Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02850081 · ClinicalTrials.gov registry record · Phase 3
Statin Neuroprotection and Carotid Endarterectomy: Safety, Feasibility and Outcomes
A Phase 3 study, sponsored by Columbia University.
- Terminated
- Registry status
- Phase 3
- Development phase
- 31
- Enrollment target
NCT02850081 is a Phase 3 study that was terminated before completion, run by Columbia University. The registered enrollment target is 31 participants.
The verdict
NCT02850081, a Phase 3 study, was terminated before completion, sponsored by Columbia University.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 31 participants
- Enrollment target
Study Summary
The investigators hypothesize that pre-operative statin use is neuroprotective at maximal doses. The goals are to determine the safety, feasibility, and efficacy of maximizing statin doses for two weeks (12-18 days) prior to CEA using change in performance on a battery neuropsychometric tests as outcome measure. Study will recruit patients based on their preexisting statin regimen. The investigators hypothesize that in asymptomatic CEA patients: 1) Pre-operative statin use is neuroprotective against early cognitive dysfunction (eCD) and lowers the risk of early mortality. 2) Maximal doses may be essential in achieving optimal neuroprotection against eCD.
Interventions
- OTHER Placebo
- DRUG Statin
- DRUG Atorvastatin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 31 participants |
| Start Date | 2017-06-01 |
| Est. Completion | 2020-03-31 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02850081
The ClinicalTrials.gov registry entry for NCT02850081 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 31 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Columbia University, which has 958 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT02850081 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02850081 about?
NCT02850081 is a clinical study titled "Statin Neuroprotection and Carotid Endarterectomy: Safety, Feasibility and Outcomes". The investigators hypothesize that pre-operative statin use is neuroprotective at maximal doses. The goals are to determine the safety, feasibility, and efficacy of maximizing statin doses for two weeks (12-18 days) prior to CEA using change in performance on a battery neuropsychometric tests as out...
What is the current status of trial NCT02850081?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 31 participants. The study started on 2017-06-01. Estimated completion is 2020-03-31.
What interventions are being tested in trial NCT02850081?
The interventions under investigation include: Placebo (OTHER), Statin (DRUG), Atorvastatin (DRUG).
Who is sponsoring clinical trial NCT02850081?
This trial is sponsored by Columbia University, which has 958 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.